Michael Zand – Page 1455

3 Key Things Every CAR-T Investor Should Watch – Madison.com

2017-07-25 Michael Zand NEWS

India setting out guidelines for stem cell research – The Pharma Letter (registration)

The Pharma Letter (registration)India setting out guidelines for stem cell researchThe Pharma Letter (registration)Stem cells are expected to dramatically improve the ability of drug companies to screen new drugs for side effects much earlier in the de… Continue reading

2017-07-25 Michael Zand NEWS

Harnessing the power of CRISPR through accurate sample prep – News-Medical.net

News-Medical.netHarnessing the power of CRISPR through accurate sample prepNews-Medical.netCRISPR technology burst onto the scene in 2012,1 and has been a staple of scientific research ever since. CRISPR offers the promise of personalized medicine on a… Continue reading

2017-07-25 Michael Zand NEWS

3 Key Things Every CAR-T Investor Should Watch — The Motley Fool – Motley Fool

3 Key Things Every CAR–T Investor Should Watch
Madison.com
But the long-term risks of CAR-T are still unknown. Delivering genetic material via a virus vector — a method used to transform regular T-cells into CAR–T cells — could have unknown, long-lasting impacts. Patients in these trials haven’t been …

and more »

2017-07-25 Michael Zand NEWS

French Biotech gets an EU CRISPR Patent for CAR-T Research – Labiotech.eu (blog)

Labiotech.eu (blog)French Biotech gets an EU CRISPR Patent for CAR-T ResearchLabiotech.eu (blog)The new European patent granted to Cellectis covers the use of RNA-guided endonucleases in primary T cells, which includes both the Cas9 and Cpf1 versions o… Continue reading

2017-07-25 Michael Zand NEWS

French Biotech gets an EU CRISPR Patent for CAR-T Research – Labiotech.eu (blog)

French Biotech gets an EU CRISPR Patent for CAR-T ResearchLabiotech.eu (blog)The new European patent granted to Cellectis covers the use of RNA-guided endonucleases in primary T cells, which includes both the Cas9 and Cpf1 versions of CRISPR. The paten… Continue reading

2017-07-25 Michael Zand NEWS

Editas Medicine, Inc. (NASDAQ:EDIT) Experiences Lighter than Usual Trading Volume – First News 24

Editas Medicine, Inc. (NASDAQ:EDIT) Experiences Lighter than Usual Trading VolumeFirst News 24CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotell… Continue reading

2017-07-25 Michael Zand NEWS

Lilly, Nektar to co-develop new immunotherapy – PharmaTimes

Seeking Alpha

3 Key Things Every CAR-T Investor Should Watch — The Motley Fool
Motley Fool
The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn’t mean CAR-T stocks are out of the woods just yet.
Biotech Bonanza: The Next Leg Up | Seeking AlphaSeeking Alpha

all 2 news articles »

2017-07-25 Michael Zand NEWS

1
…
1,453
1,454
1,455
1,456
1,457
…
3,823

PharmaTimes

Lilly, Nektar to co-develop new immunotherapy
PharmaTimes
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million. NKTR-358 is a potential …
Nektar Therapeutics – NKTR – Stock Price Today – ZacksZacks Investment Research

all 47 news articles »

Login

Cart

All posts by: Michael Zand

3 Key Things Every CAR-T Investor Should Watch – Madison.com

India setting out guidelines for stem cell research – The Pharma Letter (registration)

Harnessing the power of CRISPR through accurate sample prep – News-Medical.net

3 Key Things Every CAR-T Investor Should Watch — The Motley Fool – Motley Fool

French Biotech gets an EU CRISPR Patent for CAR-T Research – Labiotech.eu (blog)

French Biotech gets an EU CRISPR Patent for CAR-T Research – Labiotech.eu (blog)

Editas Medicine, Inc. (NASDAQ:EDIT) Experiences Lighter than Usual Trading Volume – First News 24

Lilly, Nektar to co-develop new immunotherapy – PharmaTimes